Saturday 30th May 2020
Biometrics, Analytics and Data Science: The Way Forward in the Digital World
Digital Analytics to Guide Development and Support Post-marketing Evaluation of Biosimilars – Pramod Kumar Reddy Pundra, Dr Reddy’s Laboratories
R – A Contender for SAS in Data Analytics – Srinivas Alla, Novartis
Data and its Acuity – Rajkumar Pillay, SIBM-Hyderabad
Digital Disruption in Healthcare and Data Science – Sugam Salvi, PPD
R Programming in Clinical Trial Data Analysis – Introduction – Shrishaila Patil, Navitas Data Sciences
Mining Golden Gems in Clinical Trial Data for Exploring Novel Therapeutics Using Data Science – Jagruti Desai, PAREXEL
Collaborations Between Data Operations and Clinical Operations – Nikunj Patel, CBCC
Listen to the virtual SDE here
The Bengaluru SDE was the second virtual India SDE of the year and was chaired by Shrishaila Patil, Vice President, Navitas Data Sciences. The theme was “Biometrics, Analytics and Data Science: The Way Forward in the Digital World”, and the event was a great success. The PHUSE SDE was free to attend and open to all, the results of which were unprecedented, with over 1,000 people registered and 500+ attendees on the day.
The day consisted of eight presentations from industry SMEs/experts/thought leaders, an engaging Q&A session with the audience and a buzz around the PHUSE social media platforms and App. The morning session started with a welcome note from Sarvesh Singh, PHUSE APAC Director, sharing all the good work done by PHUSE, globally, and volunteer opportunities for people to contribute in various PHUSE Working Groups/initiatives.
Shrishaila set the tone by saying: “Knowledge sharing must continue. Scientific innovation is challenged more than ever before due to the ongoing COVID-19 crisis. We are all in this together. We all are adapting in this new world. It’s virtual and it’s digital. Let us all begin this event with a positive note and hope that, ultimately, SCIENCE WILL WIN.”
In the first half of the day, various key aspects of data science were discussed, with practical examples, such as:
The role of digital analytics for post-marketing evaluation of biosimilars
R programming language as a serious contender for SAS in data analytics
The impact of big data and its power to influence business decisions
Machine learning and NLP for pharma applications
Digital disruption in healthcare.
After lunch, further topics around the success of clinical trials were discussed in detail:
Challenges and validation of R packages to ensure regulatory compliance
Leveraging data mining to explore novel therapeutics
Essence of collaboration across data providers, data analysts, clinical development teams
Shrishaila Patil, Navitas Data Sciences